France· FR:63745833
LANSOYL FRAMBOISE, gel oral en récipient unidose
A medicinal product containing paraffine liquide, registered in France by KENVUE FRANCE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PARAFFINE LIQUIDE
- Manufacturer
- KENVUE FRANCE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 3
- cip1334009354446229 récipient(s) unidose(s) PVC de 15 g
- cip133400935444790220 récipient(s) unidose(s) PVC de 15 g
- cip13340093544485110 récipient(s) unidose(s) PVC de 15 g
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d6a02773-25ae-41df-bdd9-6c30410dacc6 GET /v1/drugs/d6a02773-25ae-41df-bdd9-6c30410dacc6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63745833",
"date_amm": "1991-03-25",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "PARAFFINE LIQUIDE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gel",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about paraffine liquide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.